A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: ER Positive, Her2 Negative Breast Cancer Patients|Triple Negative Breast Cancer Patients
Interventions: DRUG: MM-121|DRUG: Paclitaxel
Sponsor: Merrimack Pharmaceuticals
Collaborators: Sanofi